SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy ($MULN) is trending as a speculative Solana-based meme coin that has polarized the community, with some investors betting on parabolic recovery plays while many others label it a continuation of the negative sentiment surrounding the original Mullen Automotive stock. Participants are actively debating the token's extreme volatility and its status as a high-risk "pump and dump" project versus a community-driven attempt to recover historical investment losses.

BioLLM

BioLLM is generating significant buzz as the self-proclaimed first neuron-integrated language model, drawing intense interest from social media communities centered on artificial intelligence and speculative crypto assets. While some enthusiasts are promoting the project as a revolutionary leap in tech, others in the community are actively debating whether the high-volume activity signals genuine innovation or speculative pump-and-dump behavior.

Maul Coin

Maul Coin is trending as community members rally behind what they describe as an organic, developer-backed project while pushing for increased social media engagement and chart listings. Discussions are heavily focused on the coin's rapid growth and the potential for a parabolic breakout as the community aims to reach higher market capitalization milestones.

Tidal Trust III - Impact Shares Women`s Empowerment ETF

Impact Shares Trust I - Impact Shares YWCA Womens Empowerment ETF

Investors are debating the role of $WOMN and other gender-diversity ETFs within the broader impact investing landscape, with discussions ranging from the strategic importance of the 'sheconomy' to critical perspectives on the fund's investment thesis and market liquidity. The ticker remains a focal point for those analyzing thematic ESG strategies and the growing capital allocation toward corporate initiatives that prioritize female empowerment.

USDX is the crypto-backed native stablecoin of the Kava DeFi hub.

USDX Stablecoin

The USDX stablecoin is currently at the center of investor focus as the market navigates the fallout from high-profile DeFi platform collapses and ongoing regulatory efforts by stablecoin issuers to integrate more deeply into the traditional U.S. financial system. Community members are actively analyzing the coin's stability and risk profile, while market participants weigh broader sentiment regarding stablecoin reliability amid recent volatility.

SPDR Series Trust - State Street SPDR S&P Oil & Gas Exploration & Production ETF

SPDR Oil & Gas Exploration & Production ETF

The SPDR Oil & Gas Exploration & Production ETF (XOP) is experiencing significant volatility and trading interest as investors weigh supply constraints, geopolitical tensions in the Middle East, and shifting production policies from OPEC+. Community sentiment remains deeply divided between those accumulating positions for a long-term commodities cycle and short-sellers betting that ongoing supply gluts and global demand concerns will drive prices lower.

CSX Corp. engages in the provision of rail-based freight transportation services. Its services include rail service, the transport of intermodal containers and trailers, rail-to-truck transfers, and bulk commodity operations. It operates through Rail and Trucking segments. The Rail segment provides rail-based transportation services including traditional rail service and the transport of intermodal containers. The Trucking segment relates to quality carriers. The company was founded in 1827 and is headquartered in Jacksonville, FL.

CSX Corp.

CSX Corp. is currently trending amid increased volatility following a mixed earnings report and the disclosure of a subpoena from the SEC related to previous accounting restatements and performance metrics. Investors are actively debating the company's long-term outlook, weighing potential M&A speculation, dividend hikes, and fleet modernization efforts against concerns over weak coal demand, operational disruptions, and a competitive landscape that has industry participants closely watching for further consolidation.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

The Linea community is intensely debating the project's potential integration with SWIFT, with many investors viewing the development as a major institutional catalyst and a strategic play within the Ethereum ecosystem. While some are optimistic about long-term value and the project's institutional backing, others express significant frustration over volatile price action, token unlock concerns, and communication gaps from the team.

Frontline Plc is an international shipping company, which engages in the ownership and operation of oil and product tankers. It also offers the seaborne transportation of crude oil and oil products. The company was founded in 1985 and is headquartered in Limmasol, Cyprus.

Frontline Plc

Frontline Ltd

Frontline is currently in the spotlight as investors track the stock's role as a major beneficiary of the volatile tanker market, with community discussions heavily centered on the impact of global trade route disruptions and elevated freight rates. Traders are closely monitoring the stock's technical performance and dividend potential, debating whether current geopolitical tensions in the Red Sea and Strait of Hormuz will provide sustained momentum for shipping equities or if the price action remains speculative.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following recent FDA clearances for its da Vinci 5 and SP systems, fueling investor optimism regarding long-term growth and market expansion. The community is actively debating the company's premium valuation and the impact of broader sector volatility, with many traders closely monitoring institutional activity and technical levels following recent price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum purchased 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The stock was purchased...

Penny Stocks To Follow Now - November 12th

Leap Therapeutics, Bitfarms, MSP Recovery, Strive, Salarius Pharmaceuticals, HIVE Digital Technologies, and Beyond Meat are the seven Penny stocks to watch today, according to MarketBeat's stock...

Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement. read more...

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering PR Newswire HOUSTON, Nov...

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

Decoy Therapeutics Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$4.12	--	--	N/A
Q4 '25	-$6.48	--	--	N/A
Q3 '24	-$36.00	--	--	N/A
Q2 '24	-$2.37	--	--	N/A
Q1 '24	-$6.70	-$6.15	8.21%	BEAT

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc